We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biovail Corporation today announced that Biovail Pharmaceuticals Canada (BPC), the Company's Canadian sales and marketing division, has entered into an agreement with Novartis Pharmaceuticals Canada Inc., a wholly owned subsidiary of Novartis AG, to market and promote cholesterol medicines Lescol, fluvastatin sodium capsules, and once-daily Lescol XL, fluvastatin sodium extended-release tablets, to Canadian specialists and primary-care physicians.
Bristol-Myers Squibb (BMS), headquartered in New York, has discontinued development of muraglitazar after determining that the type 2 diabetes drug would take several more years to get FDA approval.
A combination of aspirin and the antiplatelet drug dipyridamole has been shown to help survivors of minor strokes, according to a study published in the British journal The Lancet.
Japan-based Yakult Honsha will develop a liposomal formulation of irinotecan -- a kind of anticancer agent -- with Terumo, a pharmaceutical company based in New Jersey.
Following disappointing financial results in 2005, Italian packaging group IMA has swung into profit in the first quarter of 2006 from a loss in the first quarter of 2005, buoyed by an upswing in orders from the pharmaceutical industry.
A joint taskforce has been set up by the BioIndustry Association (BIA) and the Association of the British Pharmaceutical Industry (ABPI) to provide industry input to the expert working group set up to learn from the TGN1412 clinical trial adverse events at Northwick Park.
UnitedHealth Pharmaceutical Solutions, a division of UnitedHealthcare, is launching the second phase of its Half Tablet Program, a first-of-its-kind pill-splitting program designed to make medications more affordable for consumers and employers.